Decrease of the atrial fibrillatory rate, increased organization of the atrial rhythm and termination of atrial fibrillation by AZD7009
(2013) In Journal of Electrocardiology 46(1). p.29-35- Abstract
- Background: The atrial fibrillatory rate (APR), on AZD7009 as compared to placebo, was investigated as a potential biomarker for electrophysiological effect in early antiarrhythmic drug development. Methods: Patients with permanent AF received infusions of AZD7009 and placebo in an exploratory two-way, single-blind, randomized cross-over study. The ECG was continuously recorded, and following QRST cancellation the APR, its standard deviation (SD), the exponential decay and the atrial electrogram amplitude were determined as 3-min averages. Results: The mean APR rapidly decreased by 43% from baseline (394 +/- 38 to 225 +/- 61 fibrillations/min, p = 0.0003) on AZD7009, but not on placebo. The SD of the AFR and the exponential decay decreased... (More)
- Background: The atrial fibrillatory rate (APR), on AZD7009 as compared to placebo, was investigated as a potential biomarker for electrophysiological effect in early antiarrhythmic drug development. Methods: Patients with permanent AF received infusions of AZD7009 and placebo in an exploratory two-way, single-blind, randomized cross-over study. The ECG was continuously recorded, and following QRST cancellation the APR, its standard deviation (SD), the exponential decay and the atrial electrogram amplitude were determined as 3-min averages. Results: The mean APR rapidly decreased by 43% from baseline (394 +/- 38 to 225 +/- 61 fibrillations/min, p = 0.0003) on AZD7009, but not on placebo. The SD of the AFR and the exponential decay decreased in parallel. In 2 of 8 patients, termination of AF occurred after the APR had decreased by 58% and 53%, respectively. Conclusions: The APR may potentially serve as a biomarker of electrophysiological effects in early evaluation of rhythm control agents. (C) 2013 Elsevier Inc. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3590875
- author
- Aunes-Jansson, Maria ; Edvardsson, Nils ; Stridh, Martin LU ; Sörnmo, Leif LU ; Frison, Lars and Berggren, Anders
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Atrial fibrillatory rate, Pharmacological conversion, Atrial, fibrillation
- in
- Journal of Electrocardiology
- volume
- 46
- issue
- 1
- pages
- 29 - 35
- publisher
- Elsevier
- external identifiers
-
- wos:000313997400010
- scopus:84872138059
- pmid:23219385
- ISSN
- 1532-8430
- DOI
- 10.1016/j.jelectrocard.2012.09.002
- language
- English
- LU publication?
- yes
- id
- 53d006b0-0ad3-44ba-b6d2-53184aa46a59 (old id 3590875)
- date added to LUP
- 2016-04-01 10:40:15
- date last changed
- 2022-01-26 01:19:03
@article{53d006b0-0ad3-44ba-b6d2-53184aa46a59, abstract = {{Background: The atrial fibrillatory rate (APR), on AZD7009 as compared to placebo, was investigated as a potential biomarker for electrophysiological effect in early antiarrhythmic drug development. Methods: Patients with permanent AF received infusions of AZD7009 and placebo in an exploratory two-way, single-blind, randomized cross-over study. The ECG was continuously recorded, and following QRST cancellation the APR, its standard deviation (SD), the exponential decay and the atrial electrogram amplitude were determined as 3-min averages. Results: The mean APR rapidly decreased by 43% from baseline (394 +/- 38 to 225 +/- 61 fibrillations/min, p = 0.0003) on AZD7009, but not on placebo. The SD of the AFR and the exponential decay decreased in parallel. In 2 of 8 patients, termination of AF occurred after the APR had decreased by 58% and 53%, respectively. Conclusions: The APR may potentially serve as a biomarker of electrophysiological effects in early evaluation of rhythm control agents. (C) 2013 Elsevier Inc. All rights reserved.}}, author = {{Aunes-Jansson, Maria and Edvardsson, Nils and Stridh, Martin and Sörnmo, Leif and Frison, Lars and Berggren, Anders}}, issn = {{1532-8430}}, keywords = {{Atrial fibrillatory rate; Pharmacological conversion; Atrial; fibrillation}}, language = {{eng}}, number = {{1}}, pages = {{29--35}}, publisher = {{Elsevier}}, series = {{Journal of Electrocardiology}}, title = {{Decrease of the atrial fibrillatory rate, increased organization of the atrial rhythm and termination of atrial fibrillation by AZD7009}}, url = {{http://dx.doi.org/10.1016/j.jelectrocard.2012.09.002}}, doi = {{10.1016/j.jelectrocard.2012.09.002}}, volume = {{46}}, year = {{2013}}, }